OSE Pharma and Effimune launch liver cancer study

20 May 2016
2019_biotech_test_vial_discovery_big

Soon-to-merge French biotechs OSE Pharma (Euronext Paris :OSE) and Effimune have launched a hepatocellular carcinoma (primary liver cancer) study under a private-public collaborative program.

The MDScan (Myeloid-Derived Suppressor Cells Analysis) research program is supported by the French National Cancer Institute along with national government and further academic and research bodies, having been selected for backing following a competitive process.

Entitled Control of suppressive myeloid cells by SIRP-alpha: investigation in hepatocellular carcinoma, the study aims to measure the SIRP-alpha marker (Signal Regulatory Protein α) in liver cancer patients. It will evaluate the activity of Effi-DEM, the new checkpoint inhibitor targeting suppressor myeloid and macrophage cells.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology